词条 | Cefamandole |
释义 |
| Watchedfields = changed | verifiedrevid = 443508077 | IUPAC_name = (6R,7R)-7[(2R)-2-hydroxy-2-phenylacetyl]amino 3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | image = Cefamandole.svg | tradename = former Mandol | Drugs.com = {{drugs.com|CONS|cefamandole}} | MedlinePlus = a601206 | pregnancy_AU = B1 | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = POM | legal_US = | legal_US_comment = Discontinued | routes_of_administration = Intramuscular, intravenous | bioavailability = | protein_bound = 75% | metabolism = | elimination_half-life = 48 minutes | excretion = Mostly renal, as unchanged drug | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 34444-01-4 | CAS_supplemental = {{CAS|42540-40-9}} | ATC_prefix = J01 | ATC_suffix = DC03 | PubChem = 456255 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB01326 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 401748 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 5CKP8C2LLI | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D02344 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 3480 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1146 | C=18 | H=18 | N=6 | O=5 | S=2 | molecular_weight = 462.505 g/mol | smiles = O=C2N1/C(=C(\\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn4C)C(=O)O | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = OLVCFLKTBJRLHI-AXAPSJFSSA-N }} Cefamandole (INN, also known as cephamandole) is a second-generation broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States. The chemical structure of cefamandole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase)(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase. Cefamandole has a broad spectrum of activity and can be used to treat bacterial infections of the skin, bones and joints, urinary tract, and lower respiratory tract. The following represents cefamandole MIC susceptibility data for a few medically significant microorganisms.
CO2 is generated during the normal constitution of cefamandole and ceftazidime, potentially resulting in an explosive-like reaction in syringes.[2] See also
References1. ^http://www.toku-e.com/Assets/MIC/Cefamandole%20sodium%20salt.pdf {{CephalosporinAntiBiotics}}2. ^{{cite book |author=Stork CM |veditors=Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA |title=Goldfrank's toxicologic emergencies |chapter=Antibiotics, antifungals, and antivirals |chapterurl=https://books.google.com/books?id=cvJuLqBxGUcC&pg=PA847 |publisher=McGraw-Hill |location=New York |year=2006 |pages=847 |isbn=0-07-143763-0 |accessdate=2009-07-03}} 4 : Acetaldehyde dehydrogenase inhibitors|Cephalosporin antibiotics|Enantiopure drugs|Tetrazoles |
随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。